ANSWER: C

Rationale:

The clinical picture — confirmed ovulation but thin endometrium and hostile cervical mucus on clomiphene — is the classic manifestation of clomiphene's peripheral anti-estrogenic effect, and it is the principal reason to switch this patient to letrozole. Clomiphene occupies estrogen receptor alpha throughout the body, including the endometrium and cervix; even when hypothalamic blockade successfully drives FSH secretion and ovulation, the same receptor occupancy prevents follicle-derived estradiol from producing normal endometrial proliferation and cervical mucus changes. Letrozole induces FSH secretion through a fundamentally different mechanism: aromatase (CYP19A1) inhibition reduces estradiol biosynthesis, transiently removing hypothalamic negative feedback, but it leaves estrogen receptors unoccupied throughout the body. Because letrozole is also cleared relatively rapidly (half-life approximately 45 hours), by the time the developing follicle produces estradiol, the rising estradiol can freely bind endometrial and cervical estrogen receptors and drive normal proliferative and mucus-stimulatory responses. Switching to letrozole directly addresses the mechanism causing this patient's treatment failure.

• Option A: Option A is incorrect because increasing the clomiphene dose worsens rather than relieves the peripheral anti-estrogenic effect; the thin endometrium is caused by endometrial estrogen receptor occupancy, not by inadequate hypothalamic blockade, and higher doses increase the anti-estrogenic burden through greater zuclomiphene accumulation.
• Option B: Option B is incorrect because oral agents are not contraindicated after endometrial thinning, and escalating directly to gonadotropin injections is more costly, more intensive, and carries higher OHSS and multiple gestation risk than the appropriate next step of switching to letrozole, which addresses the mechanism with a comparably simple oral regimen.
• Option D: Option D is incorrect because adding exogenous estradiol to a regimen in which the endometrial estrogen receptors are occupied by clomiphene cannot reliably restore proliferation, since the receptors blocked by clomiphene are not available to the supplemental estrogen; the rational solution is to stop occupying the receptors by switching agents, not to attempt to overpower the blockade.
• Option E: Option E is incorrect because a GnRH agonist would produce initial flare followed by pituitary downregulation and suppression of gonadotropin secretion, which is the opposite of the sustained FSH drive needed for ovulation induction; GnRH agonists are not used as ovulation induction agents in this manner.

ANSWER: A

Rationale:

This patient demonstrates clomiphene treatment failure despite successful ovulation, which is a distinct entity from clomiphene resistance (the latter being failure to ovulate on clomiphene at all). The important clinical principle is that the cumulative pregnancy rate from clomiphene plateaus after approximately three to six ovulatory cycles; once a patient is ovulating consistently on clomiphene and has not conceived, additional ovulatory clomiphene cycles yield diminishing returns, and continued dose escalation does not meaningfully improve outcomes. The rational next step is to change strategy — most commonly to letrozole (which has demonstrated superior live birth rates in PCOS) or to gonadotropin therapy with appropriate monitoring — rather than continuing to cycle on a regimen that has already proven ineffective for conception in this patient.

• Option B: Option B is incorrect because clomiphene pregnancy rates do not rise linearly with dose; the maximal effective dose is generally considered to be 150 mg per day, doses above this are not standard and increase anti-estrogenic side effects without proportionate benefit, and escalation to 200 to 250 mg is not appropriate management.
• Option C: Option C is incorrect because failure to conceive after six ovulatory clomiphene cycles is not an absolute indication to bypass all intermediate therapies and proceed directly to IVF; a trial of letrozole or gonadotropins (with or without intrauterine insemination) is a reasonable and less invasive intermediate step before IVF in a patient with isolated ovulatory dysfunction and no other infertility factors.
• Option D: Option D is incorrect because hCG monotherapy in the mid-follicular phase is not a treatment for ovulatory dysfunction; hCG is used to trigger final oocyte maturation once a mature follicle has developed, not as a follicular recruitment agent, and it does not address the cause of this patient's treatment failure.
• Option E: Option E is incorrect because continuing an ineffective regimen indefinitely is not appropriate management for a patient with a 14-month history of infertility who has already completed an adequate clomiphene trial; ongoing failure warrants a change in therapeutic strategy rather than passive continuation.

ANSWER: D

Rationale:

WHO Group I anovulation (hypogonadotropic hypogonadism) is the one clinical setting where the choice between an FSH-only preparation and a preparation containing LH activity is decisive. The two-cell, two-gonadotropin model of ovarian steroidogenesis requires LH to stimulate theca cell production of androstenedione and testosterone, which then serve as the substrate for FSH-driven granulosa cell aromatase (CYP19A1) conversion to estradiol. In a woman with normogonadotropic anovulation, endogenous LH is present and an FSH-only preparation suffices because the patient supplies her own LH-driven androgen substrate. In hypogonadotropic hypogonadism, endogenous LH is absent or negligible; an FSH-only preparation will recruit follicular growth but cannot produce adequate estradiol because there is no androgen substrate for aromatization. This patient therefore requires a preparation providing both FSH and LH activity — human menopausal gonadotropin (which contains LH/hCG bioactivity) or recombinant FSH combined with recombinant LH.

• Option A: Option A is incorrect because FSH alone is not sufficient in the absence of endogenous LH; granulosa cell aromatase requires androgen substrate from LH-stimulated theca cells, and a hypogonadotropic patient cannot supply that substrate without exogenous LH activity.
• Option B: Option B is incorrect because recombinant FSH preparations contain no LH activity (they are produced free of LH contamination), so they cannot supply the LH stimulation that this patient lacks; recombinant FSH must be combined with recombinant LH for the hypogonadotropic patient.
• Option C: Option C is incorrect because clomiphene requires an intact hypothalamic-pituitary axis to work — it acts by blocking estrogen negative feedback to increase endogenous gonadotropin secretion — and in a hypogonadotropic patient whose pituitary is not producing gonadotropins, there is no endogenous secretion to disinhibit, rendering clomiphene ineffective.
• Option E: Option E is incorrect because hCG provides only LH-receptor stimulation and cannot replace FSH; granulosa cell follicular development and aromatase activity require FSH receptor stimulation, and hCG alone would not drive the FSH-dependent steps of follicular growth and estrogen synthesis.

ANSWER: B

Rationale:

Corifollitropin alfa is a long-acting recombinant FSH created by fusing FSH with the carboxy-terminal peptide of the hCG beta subunit, which extends its serum half-life to approximately 65 to 70 hours — roughly threefold that of standard recombinant FSH. The clinical purpose of this pharmacokinetic property is that a single injection maintains stimulatory FSH concentrations throughout approximately the first 7 days of a stimulation cycle, eliminating the need for daily FSH injections during the early follicular phase. Adding daily FSH on top of corifollitropin alfa during this first week would superimpose additional FSH exposure on an already sustained stimulatory level, risking excessive follicular recruitment and increasing OHSS risk. The correct management is to withhold supplemental FSH during the corifollitropin coverage window; conventional daily FSH is typically resumed only after approximately day 7, when corifollitropin levels decline and further stimulation is needed to complete follicular maturation.

• Option A: Option A is incorrect because corifollitropin alfa is not merely a priming dose requiring immediate daily FSH supplementation; its defining feature is sustained FSH activity across the first week, and adding daily FSH on day 3 would constitute over-stimulation.
• Option C: Option C is incorrect because corifollitropin alfa's duration of action is substantially longer than conventional recombinant FSH, and redosing every 24 hours would produce dangerous cumulative FSH exposure; a single dose covers approximately 7 days.
• Option D: Option D is incorrect because corifollitropin alfa is specifically designed for and routinely used within GnRH antagonist protocols; there is no incompatibility requiring discontinuation or cycle restart.
• Option E: Option E is incorrect because corifollitropin alfa supplies FSH activity, and routine exogenous LH supplementation is not required for all antagonist-protocol patients; LH supplementation is reserved for specific situations such as hypogonadotropic patients or selected poor responders, and the trainee's proposed daily injection on day 3 is not indicated.

ANSWER: E

Rationale:

The standard trigger-to-retrieval interval is 34 to 36 hours after hCG (or GnRH agonist) administration. The hCG trigger replicates the physiologic mid-cycle LH surge, which initiates a defined cascade of events in the preovulatory follicle: resumption of oocyte meiosis from prophase I arrest, expansion of the cumulus oophorus, and follicular wall remodeling, culminating in follicular rupture approximately 34 to 36 hours after the surge begins. Retrieval is deliberately timed to occur just before expected rupture — late enough that the oocytes have completed trigger-induced nuclear and cytoplasmic maturation, but early enough to aspirate them before spontaneous ovulation releases them from the follicle. Retrieving at 22 hours, as in the scheduling error described, risks obtaining oocytes that have not completed maturation, lowering the yield of mature, fertilizable oocytes.

• Option A: Option A is incorrect because 12 to 16 hours is too early; oocyte maturation following the trigger is not complete within that window, and retrieval that early would yield a high proportion of immature oocytes.
• Option B: Option B is incorrect because 48 to 72 hours is far too late; follicular rupture occurs at approximately 34 to 36 hours, so by 48 to 72 hours spontaneous ovulation would already have released the oocytes, and they could not be retrieved.
• Option C: Option C is incorrect because trigger-to-retrieval timing is in fact critical; the follicle ruptures at a predictable interval, and retrieval must be performed within the narrow window before rupture, not at any time within 72 hours.
• Option D: Option D is incorrect because the interval is approximately 34 to 36 hours, not 24 hours; while the natural LH surge initiates maturation, the time from surge onset to follicular rupture is approximately 34 to 36 hours, and a 24-hour interval would be premature.

ANSWER: C

Rationale:

A GnRH agonist trigger is feasible in an antagonist-protocol cycle precisely because the antagonist produces competitive, reversible blockade of pituitary GnRH receptors rather than the receptor downregulation produced by long agonist protocols. The pituitary therefore retains a responsive GnRH receptor population, and a bolus of GnRH agonist (triptorelin) elicits an endogenous surge of LH (and FSH) from preformed pituitary stores, triggering final oocyte maturation. The principal downstream consequence is twofold: first, because the endogenous LH surge is short-lived (LH half-life approximately 60 minutes) compared with the sustained stimulation of exogenous hCG (half-life 24 to 36 hours), the multiple corpora lutea receive far less prolonged LH-receptor stimulation, dramatically reducing VEGF-driven OHSS risk; second, that same brevity of luteal stimulation produces a deficient luteal phase, because the corpora lutea are not sustained as they would be by hCG, leading to inadequate progesterone production. This luteal deficiency requires either intensive luteal support or, more commonly in high-OHSS-risk patients, a freeze-all strategy with transfer in a subsequent programmed cycle.

• Option A: Option A is incorrect because the antagonist does not permanently downregulate the pituitary; it competitively and reversibly blocks GnRH receptors, and the agonist trigger produces a short — not prolonged — LH surge that reduces, not increases, OHSS risk.
• Option B: Option B is incorrect because the feasibility of the agonist trigger derives from the antagonist protocol's reversible receptor blockade, not from PCOS itself, and PCOS patients triggered with an agonist still require luteal support; they do not maintain adequate endogenous progesterone after an agonist trigger.
• Option D: Option D is incorrect because the agonist trigger is not feasible in any protocol regardless of suppression method — it cannot produce an LH surge in a long agonist protocol where the pituitary is already downregulated — and oocyte yield with an agonist trigger is generally comparable to that with hCG, not substantially lower.
• Option E: Option E is incorrect because triptorelin acts on pituitary GnRH receptors to elicit an endogenous LH surge, not on ovarian LH receptors directly, and the agonist trigger produces a deficient rather than superior luteal phase, increasing rather than eliminating the need for progesterone support.

ANSWER: A

Rationale:

The OHSS-sparing GnRH agonist trigger depends entirely on the pituitary retaining a responsive GnRH receptor population that can mount an endogenous LH surge when stimulated. In a long GnRH agonist (down-regulation) protocol, the pituitary has been deliberately downregulated and desensitized through sustained agonist exposure — this receptor downregulation is the very mechanism by which the long protocol suppresses premature LH surges. Because the GnRH receptors are already downregulated, an additional bolus of agonist cannot elicit an LH surge; the pituitary simply cannot respond. This is the fundamental protocol-dependent constraint: the agonist trigger strategy is available only in antagonist protocols, where the pituitary GnRH receptors are competitively (reversibly) blocked rather than downregulated and therefore remain capable of responding to an agonist bolus. In a long agonist protocol facing high OHSS risk, alternative strategies such as coasting, dose reduction, cycle cancellation, or a freeze-all approach after hCG triggering must be considered instead.

• Option B: Option B is incorrect because the long agonist protocol does not deplete ovarian LH receptors; the reason the agonist trigger fails is pituitary receptor downregulation preventing an LH surge, not an ovarian receptor deficit.
• Option C: Option C is incorrect because agonist triggers are not contraindicated in PCOS; in fact, the agonist trigger is a preferred OHSS-prevention strategy for high-risk PCOS patients — but only in antagonist protocols, where the pituitary can respond.
• Option D: Option D is incorrect because the inability to use an agonist trigger in the long protocol is due to pituitary downregulation, not to any incompatibility between different agonist molecules; the limitation is physiologic, not a matter of molecular mismatch.
• Option E: Option E is incorrect because the long agonist protocol leaves the pituitary downregulated and hypo-responsive, not hyper-responsive; an agonist bolus produces no meaningful surge at all, rather than an uncontrollable prolonged surge.

ANSWER: D

Rationale:

For a high-responder patient at elevated OHSS risk — as this PCOS patient with high AMH and a high antral follicle count clearly is — the GnRH antagonist protocol is preferred largely because it preserves the option of a GnRH agonist trigger. In an antagonist protocol, the pituitary GnRH receptors are competitively and reversibly blocked, so a GnRH agonist bolus at the end of stimulation can elicit an endogenous LH surge to trigger maturation; the short-lived endogenous surge provides far less prolonged luteal stimulation than hCG and dramatically reduces OHSS risk, often to near zero in high-risk patients. The long agonist protocol forecloses this critical OHSS-prevention strategy: its sustained agonist exposure downregulates the pituitary, so an agonist trigger cannot produce an LH surge, leaving hCG as the only trigger option and retaining substantial OHSS risk. The antagonist protocol is also shorter and more patient-friendly, but the decisive OHSS-related advantage is the availability of the agonist trigger.

• Option A: Option A is incorrect because the long agonist protocol does not provide superior OHSS protection in high responders; on the contrary, its inability to accommodate an agonist trigger and its sustained pituitary suppression are associated with higher OHSS risk in high-responder patients than the antagonist protocol with an agonist trigger.
• Option B: Option B is incorrect because OHSS risk is not determined solely by FSH dose and independent of the suppression strategy; the choice of protocol directly affects OHSS risk through the availability of the agonist trigger, making the protocols non-equivalent for this patient.
• Option C: Option C is incorrect because the antagonist protocol does achieve adequate follicular synchrony and oocyte yields in PCOS patients and has become the preferred protocol in this population; it does not produce unacceptably low yields.
• Option E: Option E is incorrect because the two protocols are not identical with respect to OHSS prevention; the antagonist protocol specifically enables the agonist trigger, which the long agonist protocol cannot accommodate, so they do not both rely on hCG triggering — that is precisely the difference that favors the antagonist protocol here.

ANSWER: B

Rationale:

FSH starting dose in controlled ovarian stimulation is individualized according to ovarian reserve markers, principally AMH and antral follicle count. A patient with diminished ovarian reserve, as indicated by a very low AMH and a low antral follicle count, is a poor responder and should receive a high starting FSH dose (commonly 300 to 450 IU per day) in an attempt to maximally recruit her limited follicular pool. The essential accompanying counseling point is realistic expectation-setting: exogenous FSH can only recruit follicles that already exist within the antral pool: it cannot create new follicles beyond the patient's reserve. Therefore, even maximal stimulation in a poor responder is likely to yield a low number of oocytes, and the dose is chosen to optimize recruitment within that biological ceiling rather than to overcome it.

• Option A: Option A is incorrect because it inverts the relationship between ovarian reserve and dosing: low-reserve poor responders require high, not low, FSH doses, and the rationale (high FSH sensitivity warranting low dosing) describes the high-responder situation, not diminished reserve.
• Option C: Option C is incorrect because FSH starting dose should be individualized to ovarian reserve; using a single standard dose across all patients would underdose poor responders and risk overstimulating high responders.
• Option D: Option D is incorrect because diminished ovarian reserve is not an absolute contraindication to ovarian stimulation; many such patients still attempt stimulation with their own oocytes before considering donor oocytes, which is a separate counseling discussion rather than a mandatory exclusion from stimulation.
• Option E: Option E is incorrect because minimal stimulation does not reliably produce more oocytes than high-dose gonadotropins in poor responders; minimal stimulation is an alternative strategy that accepts low yield for lower cost and burden, but it is not established to outperform high-dose stimulation for oocyte number and is not a mandatory preferred approach in all diminished-reserve patients.

ANSWER: E

Rationale:

Vaginal progesterone is the preferred route of luteal phase support for most ART patients. The pharmacologic basis is the uterine first-pass effect (also called the first uterine pass or vaginal-to-uterine transport): progesterone administered vaginally reaches the uterus directly through local diffusion and the utero-vaginal venous and lymphatic connections, producing high endometrial tissue concentrations even though systemic serum levels may be lower than with intramuscular dosing. This local delivery provides effective endometrial secretory support for implantation while avoiding the pain, sterile abscesses, and local inflammatory reactions associated with intramuscular progesterone-in-oil — exactly the complications this patient experienced. Vaginal progesterone is therefore both effective and better tolerated, making it the standard choice.

• Option A: Option A is incorrect because oral micronized progesterone undergoes extensive hepatic first-pass metabolism that markedly reduces bioavailability and produces lower, less reliable endometrial progesterone concentrations than the vaginal route; oral progesterone does not produce the highest endometrial concentrations and is generally not preferred for luteal support.
• Option B: Option B is incorrect because intramuscular progesterone-in-oil is not the only adequate route; vaginal progesterone provides effective endometrial support, so continuing a poorly tolerated intramuscular regimen is unnecessary.
• Option C: Option C is incorrect because progesterone, not estradiol, is the principal hormone required for secretory transformation and maintenance of the luteal endometrium; estradiol support may be used adjunctively in some protocols but does not replace progesterone for luteal support.
• Option D: Option D is incorrect because transdermal (skin) progesterone gels do not achieve endometrial concentrations equivalent to intramuscular injection and are not an established standard route for ART luteal support; the preferred well-tolerated alternative is vaginal progesterone, which exploits the uterine first-pass effect.

ANSWER: C

Rationale:

Late OHSS is driven by rising endogenous hCG produced by an implanting embryo in a successful pregnancy. After ovarian stimulation, the multiple corpora lutea remain capable of robust VEGF production in response to LH-receptor stimulation; if pregnancy occurs in the stimulated (fresh) cycle, the embryo's rapidly rising hCG provides a sustained second wave of LH-receptor stimulation to those corpora lutea, driving the prolonged VEGF-mediated vascular permeability that produces severe, protracted late OHSS — which can be more dangerous than early OHSS because the hCG stimulus continues to rise through early pregnancy. The freeze-all strategy prevents late OHSS by avoiding pregnancy in the stimulated cycle altogether: all embryos are cryopreserved and transferred later in a programmed cycle after the stimulated ovaries have quiesced. With no implanting embryo in the fresh cycle, there is no endogenous hCG surge to stimulate the corpora lutea, and the late OHSS cascade cannot develop. Combined with a GnRH agonist trigger (which minimizes early OHSS), freeze-all provides the most complete OHSS prevention for high-risk patients.

• Option A: Option A is incorrect because cryopreservation does not work by removing hCG bound to embryos; embryos do not carry a meaningful hCG load to be removed, and the mechanism of protection is avoidance of pregnancy-derived endogenous hCG in the stimulated cycle, not clearance of embryo-bound hormone.
• Option B: Option B is incorrect because the trigger hCG clears within days regardless of freeze-all, and the relevant stimulus for late OHSS is the endogenous hCG of an established pregnancy, not residual trigger hCG; deferring transfer protects by preventing pregnancy-derived hCG exposure to the stimulated corpora lutea, not by allowing trigger hCG to clear.
• Option D: Option D is incorrect because the freeze-all strategy does not prevent OHSS by improving embryo quality or by enabling implantation that avoids the maternal VEGF response; a successfully implanting thawed embryo in a later, non-stimulated cycle is safe because the corpora lutea of the stimulated cycle are no longer present to overproduce VEGF, not because embryo quality changed.
• Option E: Option E is incorrect because OHSS is not confined to multiple gestations; a singleton pregnancy in a stimulated cycle can drive severe late OHSS through rising endogenous hCG, so the protective mechanism of freeze-all is avoidance of fresh-cycle pregnancy, not reduction of the multiple-pregnancy rate.

ANSWER: A

Rationale:

This patient has late-onset OHSS. The distinguishing features are the timing (onset 10 or more days after retrieval, here day 13), the initial improvement of early symptoms followed by worsening, and — most tellingly — the positive and rising serum pregnancy test. Late OHSS is driven by rising endogenous hCG produced by the implanting embryo, which provides a sustained and escalating LH-receptor stimulus to the multiple corpora lutea, re-driving VEGF-mediated vascular permeability. The key clinical implication is that, unlike early OHSS (driven by the single bolus of trigger hCG, which clears over days), late OHSS is fueled by an hCG stimulus that continues to rise through early pregnancy; consequently it tends to be more severe and more prolonged, requiring close monitoring, supportive management (fluid and electrolyte management, paracentesis for tense ascites, thromboprophylaxis), and anticipation of a protracted course rather than rapid resolution.

• Option B: Option B is incorrect because this is late, not early, OHSS; the timing (day 13), the rising pregnancy test, and the worsening after initial improvement all indicate an endogenous hCG-driven late process, which will not resolve in 24 to 48 hours and is sustained by the ongoing pregnancy.
• Option C: Option C is incorrect because OHSS most certainly can occur after a pregnancy is established; indeed, the establishment of pregnancy and its rising endogenous hCG is the cause of late OHSS, not a protective factor.
• Option D: Option D is incorrect because late OHSS is generally more severe and more prolonged than early OHSS, not milder and self-limited; the rising endogenous hCG of early pregnancy sustains and worsens the process rather than allowing spontaneous resolution within days.
• Option E: Option E is incorrect because ascites and worsening distension two weeks after retrieval in a patient with a rising pregnancy test are classic for late OHSS; while ovarian torsion is a recognized complication of enlarged stimulated ovaries and must be considered if pain is acute and focal, the described picture is characteristic of late OHSS rather than unrelated to it.

ANSWER: D

Rationale:

Cabergoline is a dopamine D2 receptor agonist that serves as adjunctive prophylaxis against OHSS, and it is particularly relevant in a patient who is receiving an hCG trigger and therefore retains meaningful luteotropic hCG activity (rather than receiving the OHSS-sparing agonist trigger). Its OHSS-preventive mechanism operates at the level of the endothelial VEGF receptor: dopamine D2 receptor activation interferes with the phosphorylation and downstream signaling of VEGF receptor-2 (VEGFR2), the receptor through which VEGF increases vascular permeability. By blunting VEGFR2 signaling, cabergoline decreases the vascular permeability that produces the third-space fluid shifts of OHSS. Importantly, cabergoline reduces the incidence and severity of early OHSS in high-risk patients without substantially impairing implantation or pregnancy rates, which is why it is used as an adjunct rather than as a stand-alone solution.

• Option A: Option A is incorrect because cabergoline's OHSS-preventive effect is not mediated through prolactin suppression improving luteal progesterone; although cabergoline does lower prolactin, its relevant action here is dopaminergic interference with endothelial VEGFR2 signaling, not enhancement of corpus luteum progesterone output.
• Option B: Option B is incorrect because cabergoline is an adjunct that reduces but does not eliminate OHSS risk; it does not replace primary strategies such as the agonist trigger and freeze-all, and it is not sufficient as sole prophylaxis to eliminate severe OHSS when an hCG trigger is used.
• Option C: Option C is incorrect because cabergoline does not principally act by lowering circulating VEGF concentrations through inhibition of VEGF synthesis; its established mechanism is interference with VEGFR2 phosphorylation and signaling at the endothelium — it blunts the response to VEGF rather than removing the ligand.
• Option E: Option E is incorrect because cabergoline does not antagonize LH receptors on the corpora lutea; it acts downstream at the endothelial VEGFR2 level via dopamine D2 receptors, and it does not block the hCG-LH receptor interaction that drives VEGF production.

ANSWER: B

Rationale:

In severe OHSS, venous thromboembolism (VTE) is a leading cause of morbidity and mortality, and thromboprophylaxis with low-molecular-weight heparin is an essential component of inpatient management. Several factors converge to create a markedly prothrombotic state: hemoconcentration (reflected in this patient's hematocrit of 50%) increases blood viscosity and stasis; immobility from tense ascites and discomfort promotes venous stasis; and the hormonal milieu of early pregnancy (elevated estrogen and the procoagulant changes of pregnancy) further raises thrombotic risk. Thrombosis in OHSS can occur in unusual sites, including the upper extremities and cerebral vessels, and can be fatal. Therefore, alongside careful fluid and electrolyte management and paracentesis for tense ascites, LMWH thromboprophylaxis directly targets a leading lethal complication.

• Option A: Option A is incorrect because aggressive diuresis with high-dose furosemide is generally contraindicated in the hypovolemic, hemoconcentrated patient with OHSS; the oliguria reflects intravascular volume depletion from third-space fluid shifts, and diuresis would worsen hemoconcentration and thrombosis risk. Management of oliguria centers on judicious volume expansion, not forced diuresis.
• Option C: Option C is incorrect because the ascites of OHSS is not presumed infected and sepsis is not the principal cause of OHSS mortality; empiric broad-spectrum antibiotics are not a routine priority, whereas thromboembolism is the leading lethal complication requiring prophylaxis.
• Option D: Option D is incorrect because intravenous NSAIDs are not a definitive treatment that reverses OHSS; OHSS management is supportive, NSAIDs do not reverse the VEGF-driven process, and NSAIDs carry renal risks that are especially undesirable in a hypovolemic, oliguric OHSS patient.
• Option E: Option E is incorrect because oral combined estrogen-progestin therapy is not a priority intervention in hospitalized OHSS and would not halt the VEGF process; moreover, this patient is pregnant, making such therapy inappropriate, and the priority pharmacologic intervention is thromboprophylaxis.

ANSWER: E

Rationale:

Fluid management in severe OHSS centers on correcting the intravascular hypovolemia produced by VEGF-driven plasma extravasation while avoiding interventions that worsen the fluid shifts. Isotonic crystalloid (normal saline or a balanced isotonic solution) is the appropriate resuscitation fluid: it expands the intravascular compartment without the osmolar problems of hypotonic fluids. Hypotonic fluids are avoided because they distribute poorly within the intravascular space, can worsen hyponatremia and hypo-osmolality, and do not effectively correct the effective hypovolemia. For tense ascites causing pain, respiratory compromise, or oliguria from increased intra-abdominal pressure, ultrasound-guided paracentesis is both appropriate and therapeutic: removing the tense fluid relieves abdominal pain, improves diaphragmatic excursion and respiratory mechanics, and can improve renal perfusion by reducing intra-abdominal pressure. The combination of isotonic volume support and paracentesis for tense ascites is standard supportive care.

• Option A: Option A is incorrect because hypotonic fluids are specifically avoided in OHSS; they worsen hypo-osmolality and do not adequately support the intravascular volume, making isotonic crystalloid the correct choice.
• Option B: Option B is incorrect because strict fluid restriction is inappropriate in a hypovolemic, hemoconcentrated OHSS patient with oliguria; the problem is effective intravascular volume depletion requiring judicious volume support, not fluid overload requiring restriction.
• Option C: Option C is incorrect because the goal of fluid therapy is judicious correction of intravascular volume and symptom relief, not aggressive boluses aimed at instantly normalizing the hematocrit while disregarding the ascites; overly aggressive crystalloid can drive further third-space accumulation, and management must address the tense ascites.
• Option D: Option D is incorrect because paracentesis is not contraindicated in OHSS; it is in fact a valuable therapeutic measure for tense ascites, whereas diuretics in a hypovolemic, hemoconcentrated patient would worsen the intravascular depletion and thrombotic risk.

ANSWER: C

Rationale:

The most comprehensive OHSS-minimizing plan layers protective choices at every decision point, and each element contributes independently. A GnRH antagonist protocol is chosen because it preserves pituitary responsiveness and therefore permits a GnRH agonist trigger. A low starting FSH dose (appropriate for a high-AMH, high-antral-follicle-count PCOS patient) limits the size of the recruited follicular cohort, reducing the number of corpora lutea and thus the total VEGF burden. A GnRH agonist trigger replaces hCG, producing only a short-lived endogenous LH surge that markedly reduces early OHSS risk relative to the sustained stimulation of hCG. Finally, a freeze-all strategy with deferred frozen embryo transfer avoids pregnancy in the stimulated cycle, eliminating the rising endogenous hCG that drives severe late OHSS. Together — antagonist protocol, low-dose FSH, agonist trigger, and freeze-all — these choices provide near-complete OHSS protection for a high-risk PCOS patient with a prior severe OHSS episode.

• Option A: Option A is incorrect because it selects the highest-risk combination for this patient: a long agonist protocol forecloses the agonist trigger, a high FSH dose over-recruits the large PCOS follicular cohort, and an hCG trigger plus fresh transfer maximizes both early and late OHSS risk.
• Option B: Option B is incorrect because the antagonist protocol alone is not sufficient to prevent OHSS when combined with high-dose FSH, an hCG trigger, and fresh transfer; the protocol choice must be paired with low-dose FSH, an agonist trigger, and freeze-all to be protective.
• Option D: Option D is incorrect because a long agonist protocol cannot accommodate a GnRH agonist trigger — the downregulated pituitary cannot mount an LH surge — so this combination is internally inconsistent and not feasible as described.
• Option E: Option E is incorrect because the agonist trigger does not eliminate all OHSS risk by itself; high-dose FSH over-recruits follicles, and fresh transfer permits pregnancy-derived endogenous hCG to drive late OHSS, so aggressive stimulation with fresh transfer is not safe in this high-risk patient even with an agonist trigger.